MONOCLONAL ANTIBODIES USED IN CANCER TREATMENT

Doğan M.

Nazim Huseynli -65 International Scientific Research Congress, Baku, Azerbaycan, 30 Nisan 2021, ss.223-228

  • Yayın Türü: Bildiri / Tam Metin Bildiri
  • Basıldığı Şehir: Baku
  • Basıldığı Ülke: Azerbaycan
  • Sayfa Sayıları: ss.223-228
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Monoclonal antibodies developed for various target molecules in tumor cells have been very effective in cancer treatment in recent years. Its high specificity and relatively favorable toxicity profiles have allowed monoclonal antibodies to be included in standard treatments. Monoclonal antibodies can bind to their receptors on the surface of cancer cells, causing activation or inhibition. The mechanisms of action of monoclonal antibodies in cancer treatment are assessed under four main headings. First, the monoclonal antibody provides the activation of complement components when bound to the antigen. This causes opsonization of cancer cells and phagocytic cells lyse tumor cells. They provide antibody dependent cellular cytotoxicity or release of cytokines. Monoclonal antibodies bind to inhibitory Fc receptors, suppressing target cell activation. Finally, monoclonal antibodies bind directly to growth factor receptors, causing the death of cancer cells. Many monoclonal antibodies are used for therapeutic purposes in accordance with the specified mechanisms. Current studies are ongoing on monoclonal antibodies that are more targeted, and effective, and have reduced side and potential toxic effects.